



An Empirical Validation of the Within-subject Biospecimens Pooling Approach to Minimize Exposure Misclassification in Biomarker-based Studies

Céline Vernet, Claire Philippiat, Lydiane Agier, Antonia Calafat, Xiaoyun Ye, Sarah Lyon-Caen, Pierre Hainaut, Valérie Siroux, Enrique Schisterman, Rémy Slama

► To cite this version:

Céline Vernet, Claire Philippiat, Lydiane Agier, Antonia Calafat, Xiaoyun Ye, et al.. An Empirical Validation of the Within-subject Biospecimens Pooling Approach to Minimize Exposure Misclassification in Biomarker-based Studies. *Epidemiology*, 2019, 30 (5), pp.756-767. 10.1097/EDE.0000000000001056 . inserm-03156679

HAL Id: inserm-03156679

<https://inserm.hal.science/inserm-03156679v1>

Submitted on 3 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ABSTRACT

Background: Within-subject biospecimens pooling can theoretically reduce bias in dose-response functions issued from biomarker-based studies when exposure assessment suffers from classical-type error. However, collecting many urine voids each day is cumbersome. We evaluated the empirical validity of a within-subject pooling approach and compared several options to avoid collecting all daily urine samples.

Methods: In 16 pregnant women who collected a spot of each urine void over several nonconsecutive weeks, we compared concentrations of 10 phenols in daily, weekly and pregnancy within-subject pools. Pools were prepared from either three or all daily samples. From a simulation study using these data, we quantified bias in dose-response functions when using one to 20 urine samples per subject to assess methylparaben (a compound with moderate within-subject variability) and bisphenol A (high variability) exposures.

Results: Correlations between exposure estimates from pools of all and of only three voids per day were above 0.8 for all time windows and compounds, except for benzophenone-3 and triclosan in the daily time-window (correlations, 0.6-0.7). With one spot sample to assess pregnancy exposure, correlations were all below 0.74. Using one biospecimen led to an attenuation bias in the dose-response functions of 30% (methylparaben) and 68% (bisphenol A); four and 18 samples, respectively, were required to decrease bias to 10%.

Conclusion: For non-persistent chemicals, collecting and pooling three samples per day instead of all daily samples efficiently estimates exposures over a week or more. Collecting around 20 biospecimens can strongly limit attenuation bias for very little persistent chemicals like bisphenol A.

Keywords: exposure assessment, exposure biomarkers, measurement error, attenuation bias, pooling, sampling design, within-subject variability, phenols.

INTRODUCTION

Investigating the potential human health impact of environmental pollutants requires an accurate estimation of a proxy exposure over relevant time-windows.^{1,2} For chemicals with multiple or poorly characterized sources, given the high sensitivity of targeted biochemical assays, exposure biomarkers are the most frequently used option in human studies. However, despite its analytical accuracy, this approach may entail strong exposure misclassification. Indeed, for chemicals whose biomarker concentrations display high (within-subject) temporal variability (e.g., phenols, phthalates, dialkyl phosphates),^{3–5} relying on a single or a couple of biospecimens per subject provides a poor estimate of the average exposure over time. In the case of classical-type error, this is expected to lead to (sometimes strong) attenuation bias in dose-response relationships.^{2,6} Classical-type measurement error occurs when individual's biomarker concentrations vary around the true value, which can be approximated by the mean of repeated measurements throughout the target time window.⁷

Increasing the number of biospecimens collected from each subject mitigates attenuation bias.^{2,8} If several biospecimens are available in at least part of the study population, one can quantify biomarker concentrations in each biospecimen and use measurement error models to limit bias.^{7,9,10} This approach increases analytical costs. One alternative consists in pooling the biospecimens within-subject, which benefits from the repeated exposure information collected for each subject, without increasing analytical costs because one or a few pools are analysed per subject. This so-called *within-subject biospecimens pooling approach* has been validated theoretically,⁸ but its implementation in large-scale epidemiological studies and long exposure windows (e.g., the entire pregnancy) raises practical issues. In particular, collecting all daily urine samples may be

cumbersome; consequently, evaluating the efficiency of downgraded approaches in which only a few daily voids are sampled would help designing efficient and feasible studies.

Our aims were: 1) to evaluate the efficiency of a sampling design based on collecting three spot urine samples per day to approximate the average exposure over daily, weekly and whole pregnancy exposure windows, compared to collecting all daily urine voids; and 2) to empirically investigate the effect of within-subject temporal variability in biomarkers concentrations in actual populations on bias in dose-response functions. We used select phenols as examples of non-persistent biomarkers covering a large range of within-subject variability.

METHODS

Overview

We relied on pregnant women recruited for the SEPAGES (*Suivi de l'Exposition à la Pollution Atmosphérique durant la Grossesse et Effets sur la Santé*; Assessment of air pollution exposure during pregnancy and effects on health) cohort feasibility study, who collected a spot sample of each urine void over three pregnancy weeks.^{3,11} Urine was pooled within-subject using different approaches, from which we assessed the agreement between two estimates of daily, weekly and pregnancy exposure: one relied on pools made from all daily samples for each subject, and one on pools using fewer samples (*aim 1*). From the same exposure dataset, we generated a fictitious study, assumed phenols impacted a health outcome, and evaluated the impact on the estimated dose-response function of increasing the number of biospecimens for exposure assessment, and of using an *a posteriori* disattenuation approach⁸ (*aim 2*).

Biospecimens

Urine collection

SEPAGES-feasibility was approved by the appropriate ethical committees (CPP; CNIL; CCTIRS; ANSM). All participants provided written informed consent for biological measurements and data collection. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory did not constitute engagement in human subject research.

As detailed elsewhere,³ 30 pregnant women living in Grenoble urban area (France) collected a spot sample of each urine void in polypropylene containers during three nonconsecutive weeks (median: 13, 23, and 32 gestational weeks) between July 2012 and July 2013.

Samples were kept in the participants' refrigerators until the study staff retrieved them, aliquoted and froze them at -80°C into polypropylene cryovials at Inserm Institute for Advanced Biosciences,

Grenoble. Women recorded any missed void. Biomarkers were quantified in the 16 women with the smallest number of missed voids. Two women collected a sample of all their voids (no missing void, *group A1*), six more than 95% (*group A2*) and eight between 80 and 95% of their voids (*group B*).

Urine pools

We pooled individual samples as detailed in Figure 1. For each subject, we prepared (i) within-subject *daily pools* (seven daily pools per subject per week) using an equal volume of all voids of each day (there were on average eight voids per day); (ii) within-subject *weekly pools*, obtained by pooling an equal volume of all daily pools of each of the three weeks; and (iii) a within-subject *pregnancy pool*, obtained by pooling all weekly pools. This *ideal* approach corresponds to *protocol 1*.

In a *downgraded* pooling approach (*protocol 2*), daily pools were prepared using three randomly selected samples (instead of all in protocol 1) from each subject: one from the morning (midnight to 11:59 A.M.), one from the afternoon (12:00-5:59 P.M.) and one from the evening (6:00-11:59 PM). Weekly and pregnancy pools were prepared as in protocol 1 from these downgraded daily pools (Figure 1).

All samples were kept frozen at -80°C in 2 mL polypropylene cryovials until shipment on dry ice to the CDC (Atlanta, Georgia, USA), where all biospecimens were stored (-70°C) until analysis.

Quantification of phenol biomarkers

Total (free plus conjugated) concentrations of 2,4-dichlorophenol, 2,5-dichlorophenol, benzophenone-3, bisphenol A, bisphenol S, triclosan, butylparaben, methylparaben, ethylparaben, and propylparaben were quantified using online solid-phase extraction high-performance liquid chromatography-isotope dilution-tandem mass spectrometry.¹²

Phenols were quantified in pregnancy pools of all 16 women. Because of cost limitations, we quantified phenols in weekly pools only in the eight women of groups A1 and A2 (group A); in daily pools of a whole week in the two women from group A1; and in only one random day in group A2 (20 daily pools in total).

Aim 1: Efficiency of a downgraded within-subject pooling protocol for exposure assessment

We compared the efficiency of the *downgraded pooling* approach (*protocol 2*), with that of the *ideal pooling* approach (*protocol 1*, our reference) to provide an estimate of exposure to the ten considered phenols over exposure windows of a day, a week and the whole pregnancy (corresponding to the average of the three follow-up weeks).

For the pregnancy exposure window, we also compared exposure estimates from the ideal approach to other *downgraded* approaches based on reliance on one to eight spot samples randomly selected from all available samples collected for each of the eight women of group A:

- *Protocol 3*, relying on a single random spot sample, consistent with the typical epidemiological study published in recent years (with the difference that samples are generally not randomly selected);
- *Protocols 4 and 5*, relying on the averaged biomarker concentrations in three and eight random spot samples, respectively.

Non-detectable concentrations were replaced by instrumental readings and, for null instrumental readings, by the biomarker-specific non-null lowest instrumental reading divided by $\sqrt{2}$. Biomarker concentrations were ln-transformed.

The comparison of phenol concentrations averages (as well as creatinine and specific gravity measurements) between protocols was done using correlation coefficients, paired t-tests, Cohen's Kappa coefficients, scatter plots and Bland-Altman plots.^{13,14}

Aim 2: Impact of biomarker variability on dose-response estimates

Methods are detailed in eAppendix 1. Our approach parallels that described in a theoretical study in which biomarker concentrations were simulated,⁸ with the difference that we relied here on phenol urinary concentrations from eight spot samples randomly selected from all available biospecimens collected throughout pregnancy in eight women (group A). A bootstrap approach was used to generate populations of 3,000 subjects with one to 20 biospecimens each. We quantified bias and statistical power of epidemiological studies aiming at relating exposure to two phenol biomarkers to a continuous health outcome (assumed to correspond to child weight at 3 years). We chose two compounds, methylparaben (intraclass correlation coefficient, ICC=0.85) and bisphenol A (ICC=0.38), because of their contrasted pregnancy-specific ICCs in the studied population of eight women.³ Exposure was assumed to be assessed from biomarker concentration in one random spot sample or in within-subject pools of an increasing number of biospecimens.

Bias was estimated as the difference in percent between the mean effect estimate (β) over 1,000 studies for the surrogates of exposure and the true effect (β_{true}), divided by the true effect. Statistical power was calculated as the fraction of the 1,000 studies with a p-value for the association below 0.05.

We additionally reported *a posteriori* disattenuated effect estimates.^{2,7,8} These estimates were obtained by dividing the regression coefficient associated to each compound by the ICC of the compound. We used two pregnancy-specific ICC: ICC₁, ICC corresponding to the *true* value for this specific population, and estimated in our study population of eight women,³ and ICC₂, average ICC from previous studies of pregnant women, namely 0.45 (methylparaben) and 0.20 (bisphenol A).^{15–20} Data were analysed using STATA 12.1 (Stata Corporation).

RESULTS

Population

Each woman collected between three and 15 urine specimens per day (median, 7, 25th-75th centiles, 6-10) over three weeks (total number of samples: median, 160, 25th-75th centiles, 136-188). A median time of 8.9 weeks separated successive follow-up weeks (eTable 1).

Efficiency of a downgraded within-subject pooling protocol

Daily exposure window

In daily pools from protocol 1, detection frequencies were above 75% for all phenols except benzophenone-3 (45%). Using three voids per day (protocol 2), detection frequencies were similar for most compounds except triclosan (50%) and benzophenone-3 (30%, Table 1).

Biomarker daily averages were similar between protocols 1 and 2 for all biomarkers except bisphenol S, and triclosan, for which there was a trend of underestimation of daily averages with protocol 2 compared to protocol 1 (*t-test p* value<0.001, eFigures 1-2). Pearson correlations between ln-transformed biomarker concentrations from protocols 1 and 2 were highest for parabens ($r \geq 0.96$, Table 1) and above 0.80 for all compounds except benzophenone-3 ($r=0.57$) and triclosan ($r=0.68$).

Weekly exposure window

Detection frequencies in weekly pools were similar to those observed for the daily pools, except for butylparaben (58% in weekly pools, 85% in daily pools, Tables 1-2). Protocol 2 weekly concentration averages were similar to those of protocol 1, except for 2,5-dichlorophenol, propylparaben and bisphenol A, with median concentrations tending to be higher in protocol 2, compared to protocol 1 (eFigures 3-4). Ln-transformed weekly biomarker concentrations were

highly correlated between both protocols ($r > 0.8$), the lowest correlation being for benzophenone-3 ($r = 0.81$) and the highest for three parabens and 2,5-dichlorophenol ($r \geq 0.98$, Table 2).

Pregnancy exposure window

In pregnancy pools, detection frequencies (median, 25th-75th centiles) were similar between protocols 1 (97%, 83-100%) and 2 (97%, 90-100%), and generally lower for protocol 3 (69%, 50-88%), except for benzophenone-3 (63% [protocol 3] vs. 31% [protocols 1 and 2], Table 3).

For all biomarkers, protocols 1 and 2 pregnancy averages ($n = 16$ women) were in close agreement ($r \geq 0.86$). Regarding protocols 3-5 ($n = 8$), correlations with estimates from protocol 1 increased with the number of spot biospecimens used to assess pregnancy exposure: depending on the compounds, correlations ranged from -0.67 to 0.74 for protocol 3 (one biospecimen during pregnancy), from 0.60 to 0.92 for protocol 4 (3 biospecimens), and from 0.68 to 0.98 for protocol 5 (8 biospecimens, Table 3, Figure 2). For protocols 4-5, correlations with protocol 1 were above 0.80 for all biomarkers but bisphenols and triclosan. Scatter plots and Bland-Altman plots suggested underestimation of pregnancy exposure when using protocols 3-5, compared to protocol 1 (eFigures 5-6).

Impact of biomarker variability on dose-response estimates

One biospecimen for exposure assessment

When using one random spot sample per subject to assess exposure, the average effect estimate for methylparaben was $-71g$ (95% confidence interval [CI]: $-101, -40$), corresponding to an attenuation bias of 29% compared to the true effect of $-100g$. Power was 99% (eTable 2).

For bisphenol A, relying on a single spot sample led to an average effect estimate of -31 g (95% CI: -76, 16; attenuation bias, 69%). Power was 27% (eTable 3).

A posteriori disattenuation using study-specific ICCs (ICC₁) reduced the attenuation bias to 16% (methylparaben) and 19% (bisphenol A). By contrast, disattenuation applied with an average value of the biomarker-specific ICC from external studies (ICC₂) overcorrected the effect estimate for both biomarkers: bias was +58% for methylparaben (compared to -29% without correction) and +54% for bisphenol A (compared to -69%, eTables 2-3).

For both compounds, type I error rate did not increase (5%) when no effect of the true exposure was assumed (data not shown).

Increasing the number of biospecimens

Four (methylparaben) and 18 (bisphenol A) samples, were required to limit bias below 10% (Figure 3). If disattenuation was applied using study-specific ICCs, the numbers of samples required were two (methylparaben) and three (bisphenol A).

DISCUSSION

Assessing exposure biomarkers from one spot biospecimen per subject provides an error-prone estimate of exposure to chemicals with strong within-subject variability. Within-subject biospecimens pooling is an efficient way to estimate exposure. We compared four downgraded protocols with an ideal approach to provide insight about whether the within-subject biospecimens collection could be simplified without increasing error. Within-subject pooling of three samples per day was almost as efficient as collecting all daily samples to assess exposure averages over short (one week) to longer time periods (the whole pregnancy) for phenols with relatively short elimination half-lives. This was also the case for shorter (daily) time windows, except for benzophenone-3 and triclosan. When the entire pregnancy was the targeted exposure window, collecting 3 to 8 random spot biospecimens was almost as efficient as collecting all or three samples per day for several weeks, but not for all chemicals.

Exposure misclassification from reliance on spot biospecimens entails bias in dose-response functions; we provided an empirical estimation of the amplitude of the corresponding attenuation bias, which was strong for compounds with high within-subject variability such as bisphenol A. Increasing the number of biospecimens collected per subject reduced the attenuation bias and increased statistical power. Applying the ICC-based *a posteriori* disattenuation method⁸ corrected part of the attenuation bias. The same approach using external ICCs derived from the literature increased the amplitude of the bias, showing the strong sensitivity of this method to the ICCs used.

Study considerations

By comparing exposure estimates in a small group of women (n=8), we may have reduced the variability of exposure biomarkers, possibly increasing measured correlations. However, the

number of biospecimens analysed (n=124) to make these comparisons was large. Missed voids may have artificially increased correlations between the two within-subject pooling approaches, by lowering the number of specimens in the ideal pooling approach. We limited this problem by selecting women with few missed voids.

There are several ways to combine biospecimens within-subject. We created equal-volume pools, the simplest option in practice. Alternatives include pooling proportionally to the total volume of each void (a rather cumbersome approach), or taking into account the dilution of each urine sample (e.g., pooling volumes proportional to urine dilution). All pooling protocols were similarly affected by this choice, which might not strongly impact the agreement between the compared pooling protocols. The present study was restricted to a specific population and select chemicals. Hence, generalization of our results should be considered with great caution, as we discussed elsewhere.³ In the simulation, we assumed that measurement error was of classical type, a reasonable assumption for exposure biomarkers.^{7,21}

Assessing exposure over time windows of various lengths

For an exposure window of several weeks (typically the whole pregnancy), biomarker concentrations from a single random spot sample were, in general, in poor agreement with pregnancy exposure averages from the ideal protocol 1, confirming that relying on a single random spot sample does not accurately represent the pregnancy average. Increasing the number of biospecimens per subject improved the agreement for most of the studied chemicals, with fair agreement with protocol 1 pregnancy exposure averages when relying on three to eight random biospecimens, except for triclosan and bisphenols. However, although the exposure ranking was preserved (as seen from the correlation coefficients), when using 3-8 spot samples, the pregnancy average concentration was generally not perfectly estimated. This may not be an issue when one is

interested in estimating the slope of a dose-response function assumed to be linear, but becomes one when dose-response functions are not linear, or for biomonitoring studies. For chemicals with variability such as that of ethylparaben, triclosan and bisphenols, relying on eight random spot samples to assess pregnancy exposure may not be enough. Our previous study in the same population reported high within-subject variability for these compounds.³ In contrast to protocols relying on random spot samples, agreement with the ideal approach was high for all biomarkers when repeatedly collecting three daily samples, which confirmed that this approach is efficient to assess exposure over both short and long exposure windows, even for some of the chemicals with highly variable concentrations.

Efficiently characterizing the average exposure over a week could be achieved collecting three biospecimens per day that week. When it came to characterizing exposure over a day, the approach was still efficient, except for benzophenone-3 and triclosan (correlations in the 0.5-0.7 range). However, caution is required in interpreting these results, as these biomarkers had the lowest detection frequencies.

For a few chemicals (e.g., bisphenol A and triclosan for the daily window; 2,5-dichlorophenol, propylparaben and benzophenone-3 for the weekly window), exposure averages differed between protocols 1 and 2, but exposure rankings were preserved for all compounds except triclosan in the daily window. Results for triclosan are quite consistent across exposure windows; be it for exposure ranking or dose-response function estimation, collecting half a dozen of biospecimens in the exposure window of interest may not be sufficient to assess exposure.

Bias in dose-response functions

Attenuation in regression analyses is well-known in the context of classical-type error.^{7,8,21} Using real data, we quantified the attenuation bias in regression parameters when a single error-prone

biomarker measurement is used as surrogate of the true underlying exposure. Our findings confirm theoretical results according to which bias is related to ICC,^{2,7,8} e.g., Perrier et al.⁸ who, using simulated exposure data, reported an attenuation bias of 80% for highly variable biomarker concentrations (ICC=0.2), and of 40% for chemicals with less variable concentrations (ICC=0.6). Without *a posteriori* disattenuation, four samples were required for methylparaben and 18 for bisphenol A to limit bias below 10%, compared to six and 35 samples, respectively, in Perrier et al.⁸ Hence, we observed an attenuation bias of lower magnitude and a smaller number of biospecimens required to efficiently reduce bias. This may be due to the relatively high ICCs values in our study population, compared to those assumed by Perrier et al.⁸ Our overall assessment is that a few (3-5) biospecimens over a specific time window are required for chemical biomarker with a relatively low within-subject variability, while for highly variable chemical biomarkers, at least one or two dozen biospecimens are needed.

A posteriori disattenuation, a simple technique to limit the impact of classical-type measurement error on dose-response function estimates, partly reduced the attenuation bias when using the ICCs observed in our population, which differed from the perfect correction observed by Perrier et al.⁸ Perrier et al. simulated data using a predefined ICC, while we estimated ICCs from a small sample size (n=8 women), which may have reduced the precision of the ICCs estimates. Using ICCs extracted from the literature overcorrected (i.e., created a bias in the opposite direction with greater magnitude) regression estimates. Discrepancies in the temporality of urine collection between studies may partly explain the lack of validity of external ICCs, because ICCs depend on the considered time window.³ Also, exposure sources, pathways and toxicokinetics of chemicals may vary between populations, resulting in different ICCs. This underlines the relevance of estimating variability for each study, e.g. by analysing multiple spot biospecimens from a subsample of the study population to correct bias using *a posteriori* disattenuation, even though within-subject

pooling is used. When population-specific ICCs are not available, employing external ICCs to correct estimates should be done with great caution, if at all.^{7,22}

Within-subject pooling approach

The downgraded within-subject pooling approach allows the investigation of short (days, weeks) or long (trimesters of pregnancy) exposure windows for the target biomarkers, despite limited efficiency for benzophenone-3 and triclosan in the shortest time windows (day) for the present study population. Overall, such an approach, without being too cumbersome for study participants, permits to combine information from many biospecimens to estimate exposure averages and reduce attenuation bias in effect estimates in dose-response functions, without increasing analytical costs because a single pooled sample per woman is analysed for a target exposure window.^{8,23} We have applied this approach in 479 pregnant women from SEPAGES couple-child cohort recruited in 2014-2017 in Grenoble area,²⁴ and in a subgroup of HELIX exposome project participants,²⁵ showing the feasibility of its implementation.

We assumed that pooling samples did not entail any error. Pooling error may exist because of technical differences (e.g., technician-related variability, instruments precision); physical conditions (e.g., ambient temperature, thawing duration);²⁶ or of lack of consideration of urinary dilution in the pooling strategy. In our study, a single technician pooled samples, limiting error due to biospecimens manipulation.

Collecting and pooling three daily urine specimens over toxicologically-relevant exposure windows has the advantage of being less cumbersome than collecting all urine voids. Compared to collecting a single spot biospecimen per subject, the logistic burden and overall study costs are increased, which may affect sample size. Some subjects may be reluctant to repeatedly collect biospecimens, but these should not be excluded since unbalanced designs (with varying number of

biospecimens per subject) can give acceptable estimates of dose-response functions, despite a slightly higher bias in effect estimates.⁸ If collecting repeated samples is only possible among a few subjects, then this should still be undertaken, to provide an internal estimate of ICCs, which could be used to apply *a posteriori* disattenuation to estimates, at least as a sensitivity analysis.

Conclusion

Whatever its sensitivity and accuracy, quantification of non-persistent chemicals in a spot biospecimen can provide a poor estimate of exposure over time windows of a day or more. One relevant alternative is repeated collection of within-subject biospecimens without pooling or a within-subject biospecimens pooling approach.⁸ We demonstrate here for a large family of chemicals and range of within-subject variability in biomarker concentrations that a sampling approach relying on repeated within-subject pooling of three daily spot samples over a target exposure window (days, weeks, whole pregnancy) can accurately estimate exposure averages over this time window, without increasing analytical costs or being excessively cumbersome. Not pooling biospecimens and measuring exposure biomarkers in each biospecimen allows reliance on measurement error models,^{7,8} further limiting bias but for a larger assay cost.

The within-subject biospecimens pooling approach appears to be a cost-efficient solution to minimize exposure misclassification related to the temporal variability of non-persistent exposure biomarkers. It may also be considered for non-persistent effect biomarkers, such as hormonal levels or seminal parameters.²⁷ While repeating (and possibly averaging) measurements within each observation unit is a basic metrological principle in other areas of health and environmental sciences, (e.g., assessment of blood pressure or air pollution exposure), it is currently seldom applied to biomarker-based studies. Within-subject collection of repeated samples, with or without

pooling, could allow epidemiologists making the best of the “biomarker revolution”²⁸ for biomarkers with high within-subject variability.

REFERENCES

1. Calafat AM, Longnecker MP, Koch HM, et al. Optimal Exposure Biomarkers for Nonpersistent Chemicals in Environmental Epidemiology. *Environ Health Perspect.* 2015;123(7):A166-A168. doi:10.1289/ehp.1510041
2. Rappaport SM, Symanski E, Yager JW, Kupper LL. The relationship between environmental monitoring and biological markers in exposure assessment. *Environ Health Perspect.* 1995;103(Suppl 3):49.
3. Vernet C, Philippat C, Calafat AM, et al. Within-Day, Between-Day, and Between-Week Variability of Urinary Concentrations of Phenol Biomarkers in Pregnant Women. *Environ Health Perspect.* 2018;126(3):037005. doi:10.1289/EHP1994
4. Casas M, Basagaña X, Sakhi AK, et al. Variability of urinary concentrations of non-persistent chemicals in pregnant women and school-aged children. *Environ Int.* 2018;121(Pt 1):561-573. doi:10.1016/j.envint.2018.09.046
5. Romano ME, Hawley NL, Eliot M, et al. Variability and predictors of urinary concentrations of organophosphate flame retardant metabolites among pregnant women in Rhode Island. *Environ Health.* 2017;16:40. doi:10.1186/s12940-017-0247-z
6. Brunekreef B, Noy D, Clausen P. Variability of exposure measurements in environmental epidemiology. *Am J Epidemiol.* 1987;125(5):892-898.
7. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM. *Measurement Error in Nonlinear Models: A Modern Perspective, Second Edition.* 2 edition. Boca Raton, FL: Chapman and Hall/CRC; 2006.
8. Perrier F, Giorgis-Allemand L, Slama R, Philippat C. Within-subject pooling of biological samples to reduce exposure misclassification in biomarker-based studies. *Epidemiology.* 2016;27(3):378-388. doi:10.1097/EDE.0000000000000460
9. Cook JR, Stefanski LA. Simulation-Extrapolation Estimation in Parametric Measurement Error Models. *J Am Stat Assoc.* 1994;89(428):1314-1328. doi:10.1080/01621459.1994.10476871

10. Schmiediche JW, Carroll RJ. The regression-calibration method for fitting generalized linear models with additive. 2003.
11. Ouidir M, Giorgis-Allemand L, Lyon-Caen S, et al. Estimation of exposure to atmospheric pollutants during pregnancy integrating space-time activity and indoor air levels: Does it make a difference? *Environ Int*. 2015;84:161-173. doi:10.1016/j.envint.2015.07.021
12. Zhou X, Kramer JP, Calafat AM, Ye X. Automated on-line column-switching high performance liquid chromatography isotope dilution tandem mass spectrometry method for the quantification of bisphenol A, bisphenol F, bisphenol S, and 11 other phenols in urine. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2014;944:152-156. doi:10.1016/j.jchromb.2013.11.009
13. Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat Methods Med Res*. 1999;8(2):135-160. doi:10.1177/096228029900800204
14. Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. *J Biopharm Stat*. 2007;17(4):571-582. doi:10.1080/10543400701329422
15. Braun JM, Kalkbrenner AE, Calafat AM, et al. Variability and Predictors of Urinary Bisphenol A Concentrations during Pregnancy. *Environ Health Perspect*. 2011;119(1):131. doi:10.1289/ehp.1002366
16. Braun JM, Smith KW, Williams PL, et al. Variability of Urinary Phthalate Metabolite and Bisphenol A Concentrations before and during Pregnancy. *Environ Health Perspect*. 2012;120(5):739-745. doi:10.1289/ehp.1104139
17. Jusko TA, Shaw PA, Snijder CA, et al. Reproducibility of Urinary Bisphenol A Concentrations Measured During Pregnancy in the Generation R Study. *J Expo Sci Environ Epidemiol*. 2014;24(5):532. doi:10.1038/jes.2014.23
18. Meeker JD, Cantonwine DE, Rivera-González LO, et al. Distribution, variability and predictors of urinary concentrations of phenols and parabens among pregnant women in Puerto Rico. *Environ Sci Technol*. 2013;47(7):3439. doi:10.1021/es400510g

19. Philippat C, Wolff MS, Calafat AM, et al. Prenatal Exposure to Environmental Phenols: Concentrations in Amniotic Fluid and Variability in Urinary Concentrations during Pregnancy. *Environ Health Perspect.* 2013;121(10):1225-1231. doi:10.1289/ehp.1206335
20. Smith KW, Braun JM, Williams PL, et al. Predictors and Variability of Urinary Paraben Concentrations in Men and Women, Including before and during Pregnancy. *Environ Health Perspect.* 2012;120(11):1538. doi:10.1289/ehp.1104614
21. Fuller WA. *Measurement Error Models*. 1 edition. Hoboken, N.J: Wiley-Interscience; 2006.
22. Carroll RJ, Stefanski LA. Measurement error, instrumental variables and corrections for attenuation with applications to meta-analyses. *Stat Med.* 1994;13(12):1265-1282.
23. Schisterman EF, Vexler A. To pool or not to pool, from whether to when: applications of pooling to biospecimens subject to a limit of detection. *Paediatr Perinat Epidemiol.* 2008;22(5):486-496. doi:10.1111/j.1365-3016.2008.00956.x
24. Slama R, Vernet C, Nassan FL, Hauser R, Philippat C. Characterizing the effect of endocrine disruptors on human health: The role of epidemiological cohorts. *C R Biol.* August 2017. doi:10.1016/j.crv.2017.07.008
25. Vrijheid M, Slama R, Robinson O, et al. The Human Early-Life Exposome (HELIX): Project Rationale and Design. *Environ Health Perspect.* 2014;122(6):535-544. doi:10.1289/ehp.1307204
26. Schisterman EF, Vexler A, Mumford SL, Perkins NJ. Hybrid pooled–unpooled design for cost-efficient measurement of biomarkers. *Stat Med.* 2010;29(5):597-613. doi:10.1002/sim.3823
27. Tielemans E, Heederik D, Burdorf A, Loomis D, Habbema DF. Intraindividual variability and redundancy of semen parameters. *Epidemiol Camb Mass.* 1997;8(1):99-103.
28. Schisterman EF, Albert PS. The biomarker revolution. *Stat Med.* 2012;31(22):2513. doi:10.1002/sim.5499

Table 1. Daily exposure window – Descriptive statistics of the biomarker concentrations for the 20 daily pools (8 women) and agreement between estimates from protocols 1 (pooling of all urine samples/day) and 2 (pooling of 3 urine samples/day). Biomarker concentrations were In-transformed for the estimation of agreement.

Exposure biomarker	LOD (µg/L)	Protocol 1 daily pools ^a					Protocol 2 daily pools ^b					Agreement between protocols 1 and 2					ICC ^d
		% > LOD	Percentiles (µg/L)			% > LOD	Percentiles (µg/L)			Pearson (r)	Spearman (ρ)	Kappa (K)	p-value ^c				
			5 th	50 th	95 th		5 th	50 th	95 th								
2,4-dichlorophenol	0.1	90	<LOD	0.30	3.35	100	0.20	0.25	2.85	0.90	0.61	0.22	0.37	0.12 (0.00, 0.28)			
2,5-dichlorophenol	0.1	95	0.15	0.65	146	85	<LOD	0.45	110	0.97	0.90	0.54	0.06	0.11 (0.00, 0.27)			
Butylparaben	0.1	85	<LOD	1.15	74.5	85	<LOD	0.85	94.5	0.98	0.97	0.77	0.76	0.10 (0.00, 0.25)			
Ethylparaben	1.0	75	<LOD	4.70	53.6	80	<LOD	4.65	68.4	0.98	0.97	1.00	0.86	0.03 (0.00, 0.15)			
Methylparaben	1.0	100	5.55	101.35	2550	100	5.45	94.25	2070	0.98	0.96	0.85	0.61	0.27 (0.05, 0.49)			
Propylparaben	0.1	100	0.25	15.30	299	100	0.30	17.60	322	0.98	0.98	0.85	0.58	0.28 (0.05, 0.50)			
Benzophenone-3	0.2	45	<LOD	<LOD	19.5	30	<LOD	<LOD	24.5	0.57	0.44	0.26	0.25	0.26 (0.04, 0.48)			
Bisphenol A	0.1	100	0.65	1.55	6.65	100	0.65	2.00	6.95	0.88	0.84	0.62	0.06	0.21 (0.01, 0.41)			
Bisphenol S	0.1	95	0.15	0.30	1.70	95	0.15	0.40	2.05	0.93	0.88	0.55	<0.001	0.50 (0.26, 0.73)			
Triclosan	1.0	80	<LOD	2.55	45.8	50	<LOD	1.05	73.5	0.68	0.48	0.10	<0.001	0.30 (0.08, 0.53)			
Urine dilution markers																	
Creatinine (mg/dL)	NA	NA	41.1	96.5	154	NA	72.7	100	144	0.81	0.80	0.40	0.01	0.10 (0.00, 0.26)			
Specific gravity (unitless)	NA	NA	1.013	1.018	1.030	NA	1.013	1.020	1.023	0.65	0.68	0.44	0.48	0.03 (0.00, 0.15)			

LOD, limit of detection; NA, not applicable; ICC, intraclass correlation coefficient.

r indicates Pearson correlation coefficient, ρ indicates spearman correlation coefficient, K indicates Kappa coefficient (based on biomarker concentration categorized into tertiles).

^a All spot individual urine specimens of a day were pooled within-subject in equal volumes to obtain daily pools.

^b Three individual spot urine specimens of a day were pooled within-subject in equal volumes to obtain daily pools.

^c p-value of Student's t-test comparing biomarker In-transformed concentrations between daily pools from Protocols 1 and 2.

^d Within-day ICC, as reported in Vernet et al.³

Table 2. Weekly exposure window – Descriptive statistics of the biomarker concentrations for the 24 weekly pools (8 women) and agreement between estimates from protocols 1 (pooling of all urine samples/day) and 2 (pooling of 3 urine samples/day). Biomarker concentrations were In-transformed for the estimation of agreement.

Exposure biomarker	Protocol 1 weekly pools ^a					Protocol 2 weekly pools ^b					Agreement between protocols 1 and 2					ICC ^d
	LOD (µg/L)	% > LOD	Percentiles (µg/L)			% > LOD	Percentiles (µg/L)			Pearson (r)	Spearman (ρ)	Kappa (K)	p-value ^c			
			5 th	50 th	95 th		5 th	50 th	95 th							
2,4-dichlorophenol	0.1	92	<LOD	0.30	2.20	100	0.20	0.30	2.10	0.91	0.80	0.50	0.49	0.91 (0.82, 1.00)		
2,5-dichlorophenol	0.1	100	0.30	0.60	73.0	100	0.30	0.75	72.4	0.99	0.97	0.94	0.04	0.98 (0.95, 1.00)		
Butylparaben	0.1	58	<LOD	0.25	24.0	63	<LOD	0.40	32.0	0.95	0.88	0.81	0.15	0.80 (0.61, 0.99)		
Ethylparaben	1.0	79	<LOD	11.40	56.5	88	<LOD	9.20	56.8	0.98	0.96	0.88	0.48	0.85 (0.70, 1.00)		
Methylparaben	1.0	100	3.90	44.40	1670	100	5.45	51.1	1120	0.98	0.95	0.75	0.11	0.84 (0.69, 1.00)		
Propylparaben	0.1	96	0.20	4.80	174	100	0.30	6.05	123	0.98	0.95	1.00	0.01	0.90 (0.80, 1.00)		
Benzophenone-3	0.2	38	<LOD	<LOD	28.5	42	<LOD	<LOD	36.7	0.91	0.89	0.76	0.37	0.73 (0.50, 0.96)		
Bisphenol A	0.1	100	0.50	1.90	5.70	100	0.80	2.00	6.30	0.95	0.95	0.75	0.02	0.60 (0.30, 0.89)		
Bisphenol S	0.1	92	<LOD	0.30	14.4	96	0.20	0.40	18.0	0.97	0.93	0.63	0.07	0.14 (0.00, 0.39)		
Triclosan	1.0	79	<LOD	2.50	83.7	88	<LOD	2.35	96.1	0.81	0.83	0.44	0.93	0.89 (0.78, 1.00)		
Urine dilution markers																
Creatinine (mg/dL)	NA	NA	49.6	84.1	142	NA	64.2	88.0	135	0.81	0.80	0.40	0.01	0.60 (0.30, 0.89)		
Specific gravity (unitless)	NA	NA	1.009	1.016	1.023	NA	1.011	1.016	1.024	0.65	0.68	0.44	0.48	0.61 (0.32, 0.90)		

LOD, limit of detection; NA, not applicable; ICC, intraclass correlation coefficient.

r indicates Pearson correlation coefficient, ρ indicates spearman correlation coefficient, K indicates Kappa coefficient (based on biomarker concentration categorized into tertiles).

^a All individual spot urine specimens of a day were pooled within-subject in equal volume to obtain daily pools. Daily pools were pooled within-subject in equal volumes to create weekly pools.

^b Three individual spot urine specimens of a day were pooled within-subject in equal volumes for daily pools. Daily pools were pooled within-subject in equal volumes to create weekly pools.

^c p-value of Student's t-test comparing biomarker In-transformed concentrations from weekly pools from Protocols 1 and 2.

^d Within-week ICC, as reported in Vernet et al.³

Table 3. Pregnancy exposure window – Descriptive statistics of the non-transformed biomarker concentrations for the entire pregnancy exposure window estimated by various exposure models considered, and agreement between estimates from Protocol 1 (pooling of all urine samples/day), and Protocols 2 (pooling of 3 urine samples/day), 3 (on 1 random spot sample), 4 (mean of 3 random spot samples) and 5 (mean of 8 random spot samples). Biomarker concentrations were ln-transformed for the estimation of agreement.

Exposure biomarker	Protocol	N	LOD (µg/L)	% > LOD	Percentiles (µg/L)			Agreement with estimates from protocol 1				ICC ^d
					5 th	50 th	95 th	Pearson (r)	Spearman (ρ)	Kappa (K)	p-value ^c	
2,4-dichlorophenol	Pregnancy pool, Protocol 1 ^a	16	0.1	88	0.20	0.30	2.70	ref				0.50 (0.08, 0.92)
	Pregnancy pool, Protocol 2 ^b	16		94	<LOD	0.30	2.40	0.86	0.88	0.89	0.43	
	Average of 8 random spot samples, Protocol 5	8		NA	0.15	0.36	1.80	0.92	0.86	0.43	0.44	
	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	0.35	1.82	0.85	0.80	0.24	0.32	
	Single random spot sample, Protocol 3	8		75	<LOD	0.40	0.50	0.17	0.15	-0.14	0.31	
2,5-dichlorophenol												0.85 (0.69, 1.00)
	Pregnancy pool, Protocol 1 ^a	16	0.1	100	0.40	0.55	117	ref				
	Pregnancy pool, Protocol 2 ^b	16		100	0.30	1.00	103	0.99	0.97	1.00	0.52	
	Average of 8 random spot samples, Protocol 5	8		NA	0.20	0.65	65.5	0.98	0.88	0.62	0.09	
	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	1.05	67.8	0.92	0.88	0.62	0.23	
Butylparaben	Single random spot sample, Protocol 3	8		88	<LOD	0.70	13.6	0.75	0.39	0.05	0.19	0.42 (0.00, 0.87)
	Pregnancy pool, Protocol 1 ^a	16	0.1	75	<LOD	0.50	25.8	ref				
	Pregnancy pool, Protocol 2 ^b	16		75	<LOD	0.50	32.0	1.00	0.99	0.81	0.75	
	Average of 8 random spot samples, Protocol 5	8		NA	<LOD	0.20	23.4	0.95	0.92	1.00	0.04	
Ethylparaben	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	0.30	17.6	0.91	0.86	0.62	0.52	0.40 (0.00, 0.85)
	Single random spot sample, Protocol 3	8		38	<LOD	<LOD	40.5	0.73	0.44	0.24	0.42	
	Pregnancy pool, Protocol 1 ^a	16	1.0	81	<LOD	9.35	55.2	ref				
	Pregnancy pool, Protocol 2 ^b	16		88	<LOD	9.35	124	0.99	0.97	1.00	0.81	
	Average of 8 random spot samples, Protocol 5	8		NA	<LOD	1.79	55.1	0.80	0.57	0.43	0.00	

Methylparaben	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	1.94	40.1	0.84	0.57	0.43	0.00	0.85 (0.68, 1.00)
	Single random spot sample, Protocol 3	8		50	<LOD	<LOD	154	0.54	0.40	0.05	0.03	
	Pregnancy pool, Protocol 1 ^a	16	1.0	100	5.20	56.05	2600	ref	0.99	0.81	0.08	
	Pregnancy pool, Protocol 2 ^b	16		100	12.30	55.35	2950	0.98	0.99	0.81	0.08	
	Average of 8 random spot samples, Protocol 5	8		NA	3.82	18.16	764	0.95	0.98	1.00	0.01	
Propylparaben	Average of 3 random spot samples, Protocol 4	8		NA	2.57	11.36	331	0.86	1.00	1.00	0.03	0.70 (0.40, 1.00)
	Single random spot sample, Protocol 3	8		88	<LOD	12.65	7850	0.84	0.79	0.24	0.17	
	Pregnancy pool, Protocol 1 ^a	16	0.1	100	0.20	7.30	289	ref	0.98	0.62	0.01	
	Pregnancy pool, Protocol 2 ^b	16		100	0.30	9.45	324	0.99	0.92	0.62	0.05	
	Average of 8 random spot samples, Protocol 5	8		NA	0.18	2.66	98.7	0.93	0.90	0.62	0.21	
Benzophenone-3	Average of 3 random spot samples, Protocol 4	8		NA	0.13	5.37	51.4	0.90	0.90	0.62	0.21	0.28 (0.00, 0.75)
	Single random spot sample, Protocol 3	8		50	<LOD	0.70	1180	0.71	0.65	0.62	0.10	
	Pregnancy pool, Protocol 1 ^a	16	0.2	31	<LOD	<LOD	98.80	ref	1.00	1.00	0.29	
	Pregnancy pool, Protocol 2 ^b	16		31	<LOD	<LOD	173	1.00	0.85	0.62	1.00	
	Average of 8 random spot samples, Protocol 5	8		NA	0.22	0.31	15.1	0.96	0.85	0.62	1.00	
Bisphenol A	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	0.56	11.8	0.89	0.85	0.62	0.95	0.38 (0.00, 0.83)
	Single random spot sample, Protocol 3	8		63	<LOD	1.50	9.00	0.71	0.70	0.43	0.85	
	Pregnancy pool, Protocol 1 ^a	16	0.1	100	0.70	2.45	4.50	ref	0.85	0.62	0.10	
	Pregnancy pool, Protocol 2 ^b	16		100	0.80	3.05	6.10	0.88	0.79	0.62	0.01	
	Average of 8 random spot samples, Protocol 5	8		NA	0.56	1.71	2.57	0.85	0.52	0.43	0.02	
Bisphenol S	Average of 3 random spot samples, Protocol 4	8		NA	0.11	1.27	3.05	0.74	-0.49	-0.33	0.41	0.33 (0.00, 0.80)
	Single random spot sample, Protocol 3	8		88	<LOD	1.20	10.7	-0.67				
	Pregnancy pool, Protocol 1 ^a	16	0.1	94	0.20	0.45	7.30	ref	0.91	0.61	0.19	
	Pregnancy pool, Protocol 2 ^b	16		94	<LOD	0.45	8.60	0.99	0.62	0.24	0.10	
	Average of 8 random spot samples, Protocol 5	8		NA	0.16	0.31	4.72	0.68	0.59	0.24	0.09	
	Average of 3 random spot samples, Protocol 4	8		NA	<LOD	0.27	3.28	0.60	0.10	0.05	0.05	
	Single random spot sample, Protocol 3	8		50	<LOD	0.15	0.90	0.17				

Triclosan													
Pregnancy pool, Protocol 1 ^a	16	1.0	100	1.70	5.00	248	ref						0.11 (0.00, 0.58)
Pregnancy pool, Protocol 2 ^b	16		100	<LOD	4.50	259	0.97	0.86	0.62	0.56			
Average of 8 random spot samples, Protocol 5	8		NA	<LOD	1.62	10.4	0.75	0.60	0.24	0.00			
Average of 3 random spot samples, Protocol 4	8		NA	<LOD	1.51	4.91	0.65	0.48	0.24	0.00			
Single random spot sample, Protocol 3	8		75	<LOD	1.20	2.00	-0.08	-0.19	-0.17	0.01			
<i>Urine dilution markers</i>													
Creatinine (mg/dL)													
Pregnancy pool, Protocol 1 ^a	16	NA	NA	50.69	84.4	162	ref						0.54 (0.14, 0.94)
Pregnancy pool, Protocol 2 ^b	16		NA	62.99	87.5	159	0.95	0.93	0.62	0.16			
Average of 8 random spot samples, Protocol 5	8		NA	44.59	83.8	124	0.88	0.83	0.62	0.20			
Average of 3 random spot samples, Protocol 4	8		NA	18.03	70.5	163	0.87	0.74	-0.14	0.10			
Single random spot sample, Protocol 3	8		NA	15.34	88.6	229	-0.01	-0.05	0.24	0.57			
Specific gravity (unitless)													
Pregnancy pool, Protocol 1 ^a	16	NA	NA	1.009	1.016	1.025	ref						0.69 (0.39, 1.00)
Pregnancy pool, Protocol 2 ^b	16		NA	1.011	1.016	1.025	0.98	0.97	0.59	0.84			
Average of 8 random spot samples, Protocol 5	8		NA	1.010	1.017	1.022	0.91	0.83	0.62	0.77			
Average of 3 random spot samples, Protocol 4	8		NA	1.005	1.016	1.027	0.91	0.87	0.62	0.40			
Single random spot sample, Protocol 3	8		NA	1.005	1.013	1.024	0.67	0.66	0.41	0.19			

LOD, limit of detection; NA, not applicable.

r indicates Pearson correlation coefficient, ρ indicates spearman correlation coefficient, K indicates Kappa coefficient (based on biomarker concentration categorized into tertiles).

^a All individual spot urine specimens of a day were pooled within-subject in equal volumes to obtain daily pools. Daily pools were pooled within-subject in equal volumes to create weekly pools and the within-subject pregnancy pool was created by pooling equal volumes of weekly pools.

^b Three individual spot urine specimens of a day were pooled within-subject in equal volumes for daily pools. Daily pools were pooled within-subject in equal volumes to create weekly pools and the within-subject pregnancy pool was created by pooling equal volumes of weekly pools.

^c p-value of Student's t-test comparing biomarker ln-transformed concentrations between Protocol 1 and the other protocols considered

^d Within-woman ICC based on 3 random spot samples, as reported in Vernet et al.³


FIGURE LEGENDS

Figure 1. Study design (n = 16 pregnant women from SEPAGES cohort feasibility study).

Figure 2. All exposure windows – Pearson correlation coefficients (r) between Protocols 1 (equal volumes of all spot urine voids were pooled within-subject) and 2 (equal volumes of three spot urine voids were pooled within-subject for daily pools, triangle marks) for all time windows: exposure estimates over a day (n = 8 women, N = 20 daily averages), a week (n = 8 women, N = 24 weekly averages) and the whole pregnancy (based on three measurement weeks, n = 16 women, N = 16 pregnancy averages). For the whole pregnancy, estimates from Protocols 3 (+), 4 (×), and 5 (*) are also reported (8 women, 8 pregnancy averages).

Figure 3. Bias in the health effect estimate (in %) depending on the number of biospecimens pooled per subject to assess exposure (1,000 simulation runs with 3,000 subjects each; continuous health outcome, true effect $\beta_{\text{true}} = -100\text{g}$), (A), Methylparaben (ICC₁ of 0.85 and ICC₂ of 0.45). (B), Bisphenol A (ICC₁ of 0.38 and ICC₂ of 0.2).

Unpooled spot sample	
Pooled sample	









Figure 3
A



B





[Click here to access/download](#)

Supplemental Digital Content
Revised-SupplMat-Within-subject-pooling-
2018_12_18_ANONYM.docx